Creative Medical Technology (NASDAQ:CELZ) vs. MiNK Therapeutics (NASDAQ:INKT) Head to Head Review

MiNK Therapeutics (NASDAQ:INKT) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Institutional and Insider Ownership

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 20.6% of MiNK Therapeutics shares are owned by insiders. Comparatively, 2.8% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares MiNK Therapeutics and Creative Medical Technology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46 million	($2.92)	-2.93
Creative Medical Technology	$11,000.00	349.60	-$5.29 million	($3.71)	-0.59

Creative Medical Technology has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

MiNK Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.

Profitability

This table compares MiNK Therapeutics and Creative Medical Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-189.14%
Creative Medical Technology	N/A	-63.05%	-60.42%

Analyst Ratings

This is a summary of current ratings and price targets for MiNK Therapeutics and Creative Medical Technology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0	0	2	0	3.00
Creative Medical Technology	0	0	0	0	0.00

MiNK Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 337.57%. Given MiNK Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Creative Medical Technology.

Summary

MiNK Therapeutics beats Creative Medical Technology on 7 of the 12 factors compared between the two stocks.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.